Diana W. Bianchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Diana W. Bianchi has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Kirby L. Johnson
Divisions of Genetics, Tufts-New England Medical Center, Boston, Massachusetts 02111
7 shared publicationsJanet M. Cowan
Division of Genetics, Department of Pediatrics, Tufts-New England Medical Center, Boston, MA, USA
4 shared publications- Antonio Farina
Obstetric Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, Bologna, Italy
3 shared publications Olav Lapaire
Division of Genetics, Department of Pediatrics, Tufts-New England Medical Center and Floating Hospital for Children, Tufts University School of Medicine, Boston, MA, USA
3 shared publicationsPaige B. Larrabee
Division of Genetics, Departments of Pediatrics, Obstetrics, and Gynecology, Tufts‐New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA
3 shared publicationsUmadevi Tantravahi
Department of Pathology, Women and Infants Hospital, Providence, RI, USA
3 shared publications
Latest Publications
- Open Access
- 1 May 2008
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 78 (5) , 883-887
Murine Maternal Cell Microchimerism: Analysis Using Real-Time PCR and In Vivo Imaging1
In humans, maternal cells are present in the affected tissues of children with inflammatory myopathy, scleroderma, and neonatal lupus. It is unknown
- 1 May 2008
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 78 (5) , 883-887
Open AccessMurine Maternal Cell Microchimerism: Analysis Using Real-Time PCR and In Vivo Imaging1
In humans, maternal cells are present in the affected tissues of children with inflammatory myopathy, scleroderma, and neonatal lupus. It is unknown
- Open Access
- 1 January 2008
- Published by Springer Nature
- Vol. 444, 303-309
Method for Extraction of High-Quantity and -Quality Cell-Free DNA from Amniotic Fluid
Circulating cell-free fetal deoxyribonucleic acids (cffDNAs) are promising biomarkers with various potential clinical applications. Second and third trimester amniotic fluid (AF) is a rich source of cffDNAs. Further improvements to the original protocol for the extraction of cffDNAs from AF supernatant resulted in statistically significant higher yields of high-quality cffDNAs, allowing for a substantial majority of samples to be analyzed with subsequent molecular methods (e.g., comparative genomic hybridization microarrays) to further assess for genetic abnormalities. Several advantages have been realized with the optimized protocol. In addition to an improved yield from a greater proportion of samples compared with the original protocol, the current method, using large silico-membranes, allows for the extraction of cffDNAs from up to 10 samples in <3 h. The replacement of the original lysis buffer eliminates the need for a heating bath during the lysis step, and fewer overall steps are involved in the protocol (e.g., to reduce potential contamination). The improvements in the yield with the current protocol make it possible to augment current standard of care through the analysis of this previously unappreciated source of genetic material. Furthermore, the improvements allow for exploration of widely unknown genetic, pathophysiological, and kinetic issues of cell-free fetal DNA in AF.
- 1 January 2008
- Published by Springer Nature
- Vol. 444, 303-309
Open AccessMethod for Extraction of High-Quantity and -Quality Cell-Free DNA from Amniotic Fluid
Circulating cell-free fetal deoxyribonucleic acids (cffDNAs) are promising biomarkers with various potential clinical applications. Second and third trimester amniotic fluid (AF) is a rich source of cffDNAs. Further improvements to the original protocol for the extraction of cffDNAs from AF supernatant resulted in statistically significant higher yields of high-quality cffDNAs, allowing for a substantial majority of samples to be analyzed with subsequent molecular methods (e.g., comparative genomic hybridization microarrays) to further assess for genetic abnormalities. Several advantages have been realized with the optimized protocol. In addition to an improved yield from a greater proportion of samples compared with the original protocol, the current method, using large silico-membranes, allows for the extraction of cffDNAs from up to 10 samples in <3 h. The replacement of the original lysis buffer eliminates the need for a heating bath during the lysis step, and fewer overall steps are involved in the protocol (e.g., to reduce potential contamination). The improvements in the yield with the current protocol make it possible to augment current standard of care through the analysis of this previously unappreciated source of genetic material. Furthermore, the improvements allow for exploration of widely unknown genetic, pathophysiological, and kinetic issues of cell-free fetal DNA in AF.
- 26 September 2007
- Published by Wiley in Prenatal Diagnosis
- Vol. 27 (10) , 891-892
Prenatal diagnosis: we are the future
- 26 September 2007
- Published by Wiley in Prenatal Diagnosis
- Vol. 27 (10) , 891-892
Prenatal diagnosis: we are the future
- 25 June 2007
- Published by Wiley in Prenatal Diagnosis
- Vol. 27 (9) , 854-855
A tribute to Malcolm Ferguson‐Smith, founding editor of Prenatal Diagnosis
- 25 June 2007
- Published by Wiley in Prenatal Diagnosis
- Vol. 27 (9) , 854-855
A tribute to Malcolm Ferguson‐Smith, founding editor of Prenatal Diagnosis
- 17 May 2007
- Published by Wiley in Prenatal Diagnosis
- Vol. 27 (7) , 616-621
Array‐CGH analysis of cell‐free fetal DNA in 10 mL of amniotic fluid supernatant
Background: Previously, we showed that analysis of amniotic fluid (AF) supernatant cell‐free fetal (cff) DNA using DNA microarrays (array‐CGH) allows for detection of whole chromosome differences between test and reference DNA. Subsequent technical advances have increased both the yield and quality of extracted cffDNA. Here we determined whether array‐CGH using smaller volumes of both fresh and frozen AF cffDNA could identify fetal aneuploidy.Methods: CffDNA was extracted from 10 mL of residual AF supernatant. The test AF samples (n = 10) included one with a normal karyotype, and nine with the following fetal aneuploidies: trisomies 13 (n = 1), 18 (n = 3), 21 (n = 2), trisomy 9 mosaicism (47,XX,+ 9[18]/46,XX[2]), triploidy (69,XXY) and Turner syndrome (45,X).Results: Array‐CGH using AF cffDNA from aneuploid fetuses, compared to euploid reference AF cffDNA, detected whole chromosome aneuploidy in 8 of 9 cases tested, including the case of trisomy 9 mosaicism. The case of triploidy was not detected.Conclusions: CffDNA extracted from 10 mL AF supernatant can be analyzed using array‐CGH to correctly identify human chromosome abnormalities. This technology allows for rapid screening of AF samples for whole chromosomal changes by using routinely discarded supernatant, and may augment standard prenatal karyotyping techniques by providing additional molecular information. Copyright © 2007 John Wiley & Sons, Ltd.
- 17 May 2007
- Published by Wiley in Prenatal Diagnosis
- Vol. 27 (7) , 616-621
Array‐CGH analysis of cell‐free fetal DNA in 10 mL of amniotic fluid supernatant
Background: Previously, we showed that analysis of amniotic fluid (AF) supernatant cell‐free fetal (cff) DNA using DNA microarrays (array‐CGH) allows for detection of whole chromosome differences between test and reference DNA. Subsequent technical advances have increased both the yield and quality of extracted cffDNA. Here we determined whether array‐CGH using smaller volumes of both fresh and frozen AF cffDNA could identify fetal aneuploidy.Methods: CffDNA was extracted from 10 mL of residual AF supernatant. The test AF samples (n = 10) included one with a normal karyotype, and nine with the following fetal aneuploidies: trisomies 13 (n = 1), 18 (n = 3), 21 (n = 2), trisomy 9 mosaicism (47,XX,+ 9[18]/46,XX[2]), triploidy (69,XXY) and Turner syndrome (45,X).Results: Array‐CGH using AF cffDNA from aneuploid fetuses, compared to euploid reference AF cffDNA, detected whole chromosome aneuploidy in 8 of 9 cases tested, including the case of trisomy 9 mosaicism. The case of triploidy was not detected.Conclusions: CffDNA extracted from 10 mL AF supernatant can be analyzed using array‐CGH to correctly identify human chromosome abnormalities. This technology allows for rapid screening of AF samples for whole chromosomal changes by using routinely discarded supernatant, and may augment standard prenatal karyotyping techniques by providing additional molecular information. Copyright © 2007 John Wiley & Sons, Ltd.
- 4 April 2007
- Published by American Medical Association (AMA) in JAMA
- Vol. 297 (13) , 1489-1491
Fetomaternal Cell Trafficking and the Stem Cell Debate
The current ethical, political, and scientific debates on stem cells pitch the benefits and limitations of 2 cell types against each other, adult vs embryonic s
- 4 April 2007
- Published by American Medical Association (AMA) in JAMA
- Vol. 297 (13) , 1489-1491
Fetomaternal Cell Trafficking and the Stem Cell Debate
The current ethical, political, and scientific debates on stem cells pitch the benefits and limitations of 2 cell types against each other, adult vs embryonic s
- Open Access
- 1 March 2007
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 22 (3) , 654-661
Fetal cells participate over time in the response to specific types of murine maternal hepatic injury
BACKGROUND: In humans, fetal microchimeric cells transferred to maternal tissues during pregnancy can adopt a hepatocyte phenotype. Our objective was to determine whether fetal cells participate in the response to specific murine post-partum hepatic injuries. METHODS: Wild-type female mice were bred to males transgenic for the enhanced green fluorescent protein (GFP) (n = 42). Following delivery, we created models of chemical or surgical injury with carbon tetrachloride (CCl4) injection or by performing partial hepatectomy. Liver injury was assessed histologically. Fetal cells in maternal liver were detected and measured by real-time PCR amplification of the gfp transgene and by immunofluorescence using anti-GFP antibodies. RESULTS: PCR results showed that in chemical but not surgical injury, fetal GFP+ cells were detectable in maternal liver and spleen and that fetal cell presence was significantly increased over time following injury (4 versus 8 weeks, P = 0.006 for liver and P = 0.0006 for spleen). In some animals, following chemical injury, GFP+ cells were detected by immunofluorescence. CONCLUSIONS: The results of this preliminary study suggest that specific types of injury may elicit different fetal cell responses in maternal organs. There is a significant effect of time on fetal cell presence in liver and spleen. Furthermore, real-time PCR amplification is more sensitive than immunofluorescence for the detection of microchimeric fetal cells.
- 1 March 2007
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 22 (3) , 654-661
Open AccessFetal cells participate over time in the response to specific types of murine maternal hepatic injury
BACKGROUND: In humans, fetal microchimeric cells transferred to maternal tissues during pregnancy can adopt a hepatocyte phenotype. Our objective was to determine whether fetal cells participate in the response to specific murine post-partum hepatic injuries. METHODS: Wild-type female mice were bred to males transgenic for the enhanced green fluorescent protein (GFP) (n = 42). Following delivery, we created models of chemical or surgical injury with carbon tetrachloride (CCl4) injection or by performing partial hepatectomy. Liver injury was assessed histologically. Fetal cells in maternal liver were detected and measured by real-time PCR amplification of the gfp transgene and by immunofluorescence using anti-GFP antibodies. RESULTS: PCR results showed that in chemical but not surgical injury, fetal GFP+ cells were detectable in maternal liver and spleen and that fetal cell presence was significantly increased over time following injury (4 versus 8 weeks, P = 0.006 for liver and P = 0.0006 for spleen). In some animals, following chemical injury, GFP+ cells were detected by immunofluorescence. CONCLUSIONS: The results of this preliminary study suggest that specific types of injury may elicit different fetal cell responses in maternal organs. There is a significant effect of time on fetal cell presence in liver and spleen. Furthermore, real-time PCR amplification is more sensitive than immunofluorescence for the detection of microchimeric fetal cells.
- 31 January 2007
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 42 (1) , 12-18
Fetomaternal cell trafficking: a story that begins with prenatal diagnosis and may end with stem cell therapy
- 31 January 2007
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 42 (1) , 12-18
Fetomaternal cell trafficking: a story that begins with prenatal diagnosis and may end with stem cell therapy
- 5 September 2006
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1075 (1) , 63-73
Fetal Nucleic Acids in Maternal Body Fluids
Abstract: Our laboratory continues to be actively involved in the development of new biomarkers for prenatal diagnosis using maternal blood and amniotic fluid. We have also developed a mouse model that demonstrates that cell‐free fetal (cff) DNA is detectable in the pregnant maternal mouse. In human maternal plasma and serum we have analyzed factors that are important in the clinical interpretation of cff DNA levels. Maternal race, parity, and type of conception (natural or assisted) do not affect cff DNA levels, but maternal weight does. We have also analyzed the relationship between placental volume, using a three‐dimensionsal ultrasound examination, and cff DNA levels. Surprisingly, there is no association between these values. Finally, we are using specific disease models (such as congenital diaphragmatic hernia and twin‐to‐twin transfusion) to understand the effects of gestational age and specific pathology on fetal gene expression by analyzing cell‐free mRNA levels in maternal plasma. In the amniotic fluid we have focused on improvements in recovery of cff DNA and mRNA. By optimizing recovery we have made some interesting observations about differences in fetal DNA between blood and amniotic fluid. In addition, we have successfully hybridized cff DNA in amniotic fluid to DNA microarrays, permitting assessment of fetal molecular karyotype. We also have preliminary data on fetal gene expression in amniotic fluid. Finally, we remain actively involved in promoting noninvasive prenatal testing in the United States, such as encouraging the use of fetal DNA for fetal rhesus D assessment. On the other hand, we are cautious and concerned about the accuracy of “at‐home” kits for fetal gender detection.
- 5 September 2006
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1075 (1) , 63-73
Fetal Nucleic Acids in Maternal Body Fluids
Abstract: Our laboratory continues to be actively involved in the development of new biomarkers for prenatal diagnosis using maternal blood and amniotic fluid. We have also developed a mouse model that demonstrates that cell‐free fetal (cff) DNA is detectable in the pregnant maternal mouse. In human maternal plasma and serum we have analyzed factors that are important in the clinical interpretation of cff DNA levels. Maternal race, parity, and type of conception (natural or assisted) do not affect cff DNA levels, but maternal weight does. We have also analyzed the relationship between placental volume, using a three‐dimensionsal ultrasound examination, and cff DNA levels. Surprisingly, there is no association between these values. Finally, we are using specific disease models (such as congenital diaphragmatic hernia and twin‐to‐twin transfusion) to understand the effects of gestational age and specific pathology on fetal gene expression by analyzing cell‐free mRNA levels in maternal plasma. In the amniotic fluid we have focused on improvements in recovery of cff DNA and mRNA. By optimizing recovery we have made some interesting observations about differences in fetal DNA between blood and amniotic fluid. In addition, we have successfully hybridized cff DNA in amniotic fluid to DNA microarrays, permitting assessment of fetal molecular karyotype. We also have preliminary data on fetal gene expression in amniotic fluid. Finally, we remain actively involved in promoting noninvasive prenatal testing in the United States, such as encouraging the use of fetal DNA for fetal rhesus D assessment. On the other hand, we are cautious and concerned about the accuracy of “at‐home” kits for fetal gender detection.
- 24 February 2006
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 140A (7) , 695-703
The natural history of trisomy 12p
Trisomy of the short arm of chromosome 12 is a rare chromosomal anomaly, with an estimated incidence of 1/50,000 births. It may present as a pure trisomy (complete or incomplete), as mosaic trisomy, or with other chromosomal abnormalities. Little is known from prior reports about the natural history and life expectancy of these individuals. In this study we describe the long‐term outcome and the differences between patients with mosaic trisomy 12p compared to patients with complete trisomy. We present a series of 16 patients with trisomy 12p; 6 of them are older than 10 years. Most patients were born at term with normal or above normal birth weight. Seven were born with congenital anomalies, but no single anomaly was present in more than one individual. A clear and consistent dysmorphic facial pattern was apparent in all of the subjects. Most patients over 7 years old had a seizure disorder. All individuals exhibited developmental delay with speech affected more severely than motor skills. Six patients were described as “being social.” Six had severe behavioral problems, and seven had significant sleep disturbances. Facial features of the three adult patients were different than the younger individuals. We show here that the outcome for patients with mosaic trisomy 12p is better than the outcome in complete trisomy 12p or in trisomy 12p with other chromosomal anomalies. We also provide recommendations for the long‐term follow‐up of patients with trisomy 12p.
- 24 February 2006
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 140A (7) , 695-703
The natural history of trisomy 12p
Trisomy of the short arm of chromosome 12 is a rare chromosomal anomaly, with an estimated incidence of 1/50,000 births. It may present as a pure trisomy (complete or incomplete), as mosaic trisomy, or with other chromosomal abnormalities. Little is known from prior reports about the natural history and life expectancy of these individuals. In this study we describe the long‐term outcome and the differences between patients with mosaic trisomy 12p compared to patients with complete trisomy. We present a series of 16 patients with trisomy 12p; 6 of them are older than 10 years. Most patients were born at term with normal or above normal birth weight. Seven were born with congenital anomalies, but no single anomaly was present in more than one individual. A clear and consistent dysmorphic facial pattern was apparent in all of the subjects. Most patients over 7 years old had a seizure disorder. All individuals exhibited developmental delay with speech affected more severely than motor skills. Six patients were described as “being social.” Six had severe behavioral problems, and seven had significant sleep disturbances. Facial features of the three adult patients were different than the younger individuals. We show here that the outcome for patients with mosaic trisomy 12p is better than the outcome in complete trisomy 12p or in trisomy 12p with other chromosomal anomalies. We also provide recommendations for the long‐term follow‐up of patients with trisomy 12p.